Integrated Diagnostics Holdings reaffirmed revenue guidance for the fiscal year 2023. Considering their strong first half results, the solid strategies in place, and the positive momentum enjoyed by the Egyptian and Jordian subsidiaries, the company reaffirms their guidance of full-year conventional revenue (excluding Covid-19-related contributions) year-on-year growth of around 30% for fiscal year 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3155 USD | -8.42% | -9.86% | -11.13% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.13% | 189M | |
-14.92% | 84.68B | |
+13.30% | 81.12B | |
+10.92% | 29.4B | |
-12.71% | 16.73B | |
-3.06% | 16.36B | |
-2.63% | 14.92B | |
-3.97% | 11.66B | |
-1.42% | 11.72B | |
-31.75% | 11.77B |
- Stock Market
- Equities
- IDHC Stock
- News Integrated Diagnostics Holdings plc
- Integrated Diagnostics Holdings Reaffirms Revenue Guidance for the Fiscal Year 2023